Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CRISPR base editor screening identifies spectrum of MEN1 mutations impacting menin inhibitors in clinical trials.

Nature communications - 9 May 2026

Bourgeois Wallace, Rice Hannah E, Wenge Daniela V, Perner Florian, Yue Hong, Regalado Brandon D, Wan George, Schroeder Jan C, Sommerschield Alba, Hatton Charlie, Singh Shivendra, Singh Sweta, Bijpuria Shipra, McKeever Brian M, Miller William H, Safer Jordan F, Iqbal Sumaiya, Perry Jennifer A, Fischer Eric S, Doench John G, McGeehan Gerard M, Cutler Jevon A, Armstrong Scott A

Abstract excerpt

Menin inhibitors have entered clinical trials for histone lysine methyltransferase 2 A (KMT2A)-rearranged and nucleophosmin 1 (NPM1)-mutant acute leukemias and are demonstrating promising activity. CRISPR base editor screening previously predicted several MEN1 (menin) mutations that have arisen in patients receiving SNDX-5613 and confer resistance. The extent to which MEN1 mutations will impact each menin...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clustered Regularly Interspaced Short Palindromic Repeats

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to CRISPR-Cas Systems

Share to Drug Resistance, Neoplasm

Share to Histone-Lysine N-Methyltransferase

Share to Myeloid-Lymphoid Leukemia Protein

Share to Nuclear Proteins

Share to Nucleophosmin

Share to Proto-Oncogene Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 42103719
DOI: 10.1038/s41467-026-72685-1
PMCID: PMC13377036

Genes

MEN1
KMT2A
NPM1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CRISPR base editor screening identifies spectrum of MEN1 mutations impacting menin inhibitors in clinical trials.PMID 42103719Read ↗

MEN1 mutations mediate clinical resistance to menin inhibition.Semantic proximity Read ↗

Emerging drug profile: menin inhibitors in NPM1-mutated and KM2A-rearranged acute myeloid leukemia.Semantic proximity Read ↗

Massively parallel assessment of human variants with base editor screens.Semantic proximity Read ↗

S125: NON-GENETIC RESISTANCE TO MENIN INHIBITION IN AML IS REVERSIBLE BY PERTURBATION OF KAT6ASemantic proximity Read ↗

Massively parallel assessment of human variants with base editor screensSemantic proximity Read ↗

A Box of Chemistry to Inhibit the MEN1 Tumor Suppressor Gene Promoting LeukemiaSemantic proximity Read ↗

Menin Inhibitors: A New Era of Targeted Therapies in Acute Myeloid Leukemia.Semantic proximity Read ↗

Menin inhibitors in the treatment of acute myeloid leukemiaSemantic proximity Read ↗

Menin inhibitors in KMT2A-rearranged and NPM1-mutated acute leukemia: A scoping review of safety and efficacySemantic proximity Read ↗

Combination Strategies with Menin Inhibitors for Acute LeukemiaSemantic proximity Read ↗

Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c).Semantic proximity Read ↗

The Menin Inhibitor SNDX-5613 (revumenib) Leads to Durable Responses in Patients (Pts) with KMT2A-Rearranged or NPM1 Mutant AML: Updated Results of a Phase (Ph) 1 StudySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.